Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 148,301 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 148,301 shares of Liquidia stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $64.76, for a total transaction of $9,603,972.76. Following the transaction, the director directly owned 1,636,941 shares of the company’s stock, valued at approximately $106,008,299.16. This trade represents a 8.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Liquidia Trading Up 1.9%

Shares of LQDA stock traded up $1.24 on Wednesday, hitting $65.25. 2,327,936 shares of the stock traded hands, compared to its average volume of 1,722,392. The firm’s 50-day moving average price is $47.90 and its two-hundred day moving average price is $40.11. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The stock has a market capitalization of $5.80 billion, a PE ratio of 466.10 and a beta of 0.58. Liquidia Corporation has a twelve month low of $11.85 and a twelve month high of $66.78.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia’s revenue for the quarter was up 4187.1% compared to the same quarter last year. As a group, analysts anticipate that Liquidia Corporation will post 2.97 EPS for the current year.

Institutional Trading of Liquidia

A number of large investors have recently bought and sold shares of the business. Caprock Group LLC bought a new position in Liquidia in the third quarter worth approximately $37,114,000. Apis Capital Advisors LLC bought a new position in Liquidia in the third quarter worth approximately $9,569,000. Farallon Capital Management LLC raised its position in Liquidia by 102.1% in the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after acquiring an additional 4,326,876 shares during the period. GSA Capital Partners LLP raised its position in Liquidia by 63.6% in the fourth quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock worth $2,179,000 after acquiring an additional 24,555 shares during the period. Finally, Tudor Investment Corp ET AL bought a new position in Liquidia in the third quarter worth approximately $1,536,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

LQDA has been the subject of a number of research analyst reports. BTIG Research raised their price target on Liquidia from $50.00 to $59.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Lifesci Capital raised Liquidia to a “strong-buy” rating in a research note on Thursday, March 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. Finally, Wells Fargo & Company increased their price objective on Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Liquidia currently has an average rating of “Moderate Buy” and a consensus target price of $55.63.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).